Company intelligence / Profile preview

Novamigra

Münster, North Rhine-Westphalia, Germanynovamigra.com ↗

Ownership: Private
Development stage: Other

Overview

NovaMigra is a clinical-stage biotechnology company based in Germany that focuses on the development of innovative treatments for migraine. The company's lead program, NM-002, is a proprietary nasal spray formulation of propranolol designed for the prophylaxis of migraine. By utilizing a nasal delivery route, NovaMigra aims to improve the pharmacokinetic profile and patient compliance compared to traditional oral beta-blockers. The company is currently advancing its clinical pipeline to provide more effective and better-tolerated preventative options for migraine sufferers.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

VRG-145

Preclinical

Beyond the preview

Go deeper on Novamigra.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novamigra.

Explore the full profile